Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function.

Maillet M, Davis J, Auger-Messier M, York A, Osinska H, Piquereau J, Lorenz JN, Robbins J, Ventura-Clapier R, Molkentin JD.

J Biol Chem. 2010 Feb 26;285(9):6716-24. doi: 10.1074/jbc.M109.056143. Epub 2009 Dec 27.

2.

Essential roles of Her2/erbB2 in cardiac development and function.

Negro A, Brar BK, Lee KF.

Recent Prog Horm Res. 2004;59:1-12. Review.

PMID:
14749494
3.

Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein.

Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, Tymitz KM, Penninger JM, Molkentin JD.

Circ Res. 2001 Jul 6;89(1):20-5.

4.

Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation.

Rybkin II, Markham DW, Yan Z, Bassel-Duby R, Williams RS, Olson EN.

J Biol Chem. 2003 May 2;278(18):15927-34. Epub 2003 Feb 17.

5.

Cardiac-specific deletion of protein phosphatase 1β promotes increased myofilament protein phosphorylation and contractile alterations.

Liu R, Correll RN, Davis J, Vagnozzi RJ, York AJ, Sargent MA, Nairn AC, Molkentin JD.

J Mol Cell Cardiol. 2015 Oct;87:204-13. doi: 10.1016/j.yjmcc.2015.08.018. Epub 2015 Aug 31.

6.
7.

Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function.

Gao MH, Bayat H, Roth DM, Yao Zhou J, Drumm J, Burhan J, Hammond HK.

Cardiovasc Res. 2002 Nov;56(2):197-204.

PMID:
12393090
8.

Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.

Parsons SA, Millay DP, Wilkins BJ, Bueno OF, Tsika GL, Neilson JR, Liberatore CM, Yutzey KE, Crabtree GR, Tsika RW, Molkentin JD.

J Biol Chem. 2004 Jun 18;279(25):26192-200. Epub 2004 Apr 13.

9.

Physiological growth synergizes with pathological genes in experimental cardiomyopathy.

Syed F, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, Robbins J, Dorn GW 2nd.

Circ Res. 2004 Dec 10;95(12):1200-6. Epub 2004 Nov 11.

10.
11.

Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy.

Ruan H, Mitchell S, Vainoriene M, Lou Q, Xie LH, Ren S, Goldhaber JI, Wang Y.

Circulation. 2007 Aug 7;116(6):596-605. Epub 2007 Jul 23.

12.

The transcription factor GATA-6 regulates pathological cardiac hypertrophy.

van Berlo JH, Elrod JW, van den Hoogenhof MM, York AJ, Aronow BJ, Duncan SA, Molkentin JD.

Circ Res. 2010 Oct 15;107(8):1032-40. doi: 10.1161/CIRCRESAHA.110.220764. Epub 2010 Aug 12.

13.

Decreased cardiac L-type Ca²⁺ channel activity induces hypertrophy and heart failure in mice.

Goonasekera SA, Hammer K, Auger-Messier M, Bodi I, Chen X, Zhang H, Reiken S, Elrod JW, Correll RN, York AJ, Sargent MA, Hofmann F, Moosmang S, Marks AR, Houser SR, Bers DM, Molkentin JD.

J Clin Invest. 2012 Jan;122(1):280-90. doi: 10.1172/JCI58227. Epub 2011 Dec 1.

14.

Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice.

Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4586-91. Epub 2002 Mar 19.

15.

Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability.

Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD.

Circ Res. 2006 Mar 31;98(6):837-45. Epub 2006 Mar 2.

16.

Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy.

Khoo MS, Li J, Singh MV, Yang Y, Kannankeril P, Wu Y, Grueter CE, Guan X, Oddis CV, Zhang R, Mendes L, Ni G, Madu EC, Yang J, Bass M, Gomez RJ, Wadzinski BE, Olson EN, Colbran RJ, Anderson ME.

Circulation. 2006 Sep 26;114(13):1352-9. Epub 2006 Sep 18.

17.

Cardiomyocyte-specific deletion of the coxsackievirus and adenovirus receptor results in hyperplasia of the embryonic left ventricle and abnormalities of sinuatrial valves.

Chen JW, Zhou B, Yu QC, Shin SJ, Jiao K, Schneider MD, Baldwin HS, Bergelson JM.

Circ Res. 2006 Apr 14;98(7):923-30. Epub 2006 Mar 16.

19.

Conditional disruption of calcineurin B1 in osteoblasts increases bone formation and reduces bone resorption.

Yeo H, Beck LH, Thompson SR, Farach-Carson MC, McDonald JM, Clemens TL, Zayzafoon M.

J Biol Chem. 2007 Nov 30;282(48):35318-27. Epub 2007 Sep 19.

20.

Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.

Ding W, Dong M, Deng J, Yan D, Liu Y, Xu T, Liu J.

Am J Physiol Heart Circ Physiol. 2014 Sep 1;307(5):H792-802. doi: 10.1152/ajpheart.00017.2014. Epub 2014 Jul 11.

PMID:
25015961

Supplemental Content

Support Center